전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

Breast Cancer · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleTG Therapeutics, Inc.Phase 1

brentuximab vedotin (Adcetris, TGR-1202 + brentuximab vedotin)

Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Phase1#antibody-drug-conjugate#TG
Trials 1Status Active
CGTLimited DatastaleNantes University HospitalPhase 2

nivolumab (Opdivo, TIL + IL-2 + Nivolumab)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleI-Mab Biopharma US LimitedPhase 1

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

infliximab, adalimumab, etanercept (TNF blockers, TNF blockers (infliximab, adalimumab, etanercept))

Arthritis, Rheumatoid; Spondylitis, Ankylosing · Arthritis, Rheumatoid

#ArthritisRheumatoid#Antibody#Approved#monoclonal-antibody#Arthritis+3
Trials 1Status Active
AntibodyLimited DatastaleUniversity of CalgaryApproved

adalimumab (Humira, TNFa Antagonist - Adalimumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of CalgaryApproved

TNFa Antagonist - Infliximab (TNFa Antagonist - Infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

JS001 (TORIPALIMAB INJECTION, TORIPALIMAB INJECTION(JS001 ))

Biliary Tract Cancer (BTC) · Biliary Tract Cancer (BTC)

#BiliaryTractCancerBTC#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleDaping Hospital and the Researc…Phase 2

TP + Cetuximab + Tislelizumab (TP + Cetuximab + Tislelizumab)

LA HNSCC · LA HNSCC

#LAHNSCC#Antibody#Phase2#monoclonal-antibody#Daping
Trials 1Status Recruiting
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

TPF, radiotherapy and cetuximab (TPF, radiotherapy and cetuximab)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleChia Tai Tianqing Pharmaceutica…Phase 2

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

RAS/BRAF Wild Type Colorectal Cancer · RAS/BRAF Wild Type Colorectal Cancer

#RASBRAFWildTypeColorectalCancer#Antibody#Phase2#monoclonal-antibody#RAS+2
Trials 1Status Recruiting
CGTLimited DatastaleBellicum Pharmaceuticals, Inc.Phase 1

TROP2-CAR-NK Cells (TROP2-CAR-NK Cells)

Colorectal Cancer; Minimal Residual Disease · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

nivolumab (Opdivo, TRX518 with nivolumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
AntibodyLimited DatastaleLeap Therapeutics, Inc.Phase 1

pembrolizumab (Keytruda, TRX518 with pembrolizumab)

Solid Tumors · Solid Tumors

#SolidTumors#Antibody#Phase1#monoclonal-antibody#Leap
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

TSLPR-CART (TSLPR-CART)

B-All; Acute Lymphoblastic Leukemia · B-All

#B-All#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active

88 / 103 pages

← PreviousNext →